Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 15 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Guillaume B.

Canada

USD 15 /hr

Pharma & Life Sciences Consultant | Evidence, Data & Writing | Data analysis

Profile Summary

Clinical research professional and PhD-trained biologist with over 13 years of experience across preclinical, early-phase, and Phase 3 clinical studies in oncology, immunology, and respiratory diseases. I have led and coordinated complex, cross-functional clinical research projects in both academic and industry settings, working closely with investigators, sponsors, CROs, and regulatory bodies. My expertise includes scientific and medical writing, protocol and feasibility assessment, evidence synthesis, and interpretation of clinical and operational data. I am highly experienced in translating complex clinical and research data into clear, structured, and decision-ready documents for diverse stakeholders, including investigators, sponsors, and regulatory teams. With hands-on experience in data capture systems, clinical databases, and trial management tools, I bring a rigorous, detail-oriented approach to data analysis, documentation, and quality oversight. My background spans the full research continuum—from bench to bedside—allowing me to support biotech, pharma, and research organizations with high-quality scientific content, data-driven insights, and research strategy support.

Subject Matter Expertise

• ☆ Microbiology
• ☆ Molecular Biology
• ☆ RNA Synthesis
• ☆ Ecology
• ☆ Clinical Microbiology
• ☆ Vaccine Development
• ☆ Clinical Trials
• ☆ Clinical Trial Design
• ☆ Patient Recruitment
• ☆ Clinical Data Management
• ☆ Clinical Trials Data Analysis
• ☆ Oncology
• ☆ Radiation Therapy
• ☆ Regulatory Affairs
• ☆ Pharmaceutical Management
• ☆ Pharmaceutical Technology
• ☆ Six Sigma

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Clinical Trial Documentation, Medical Writing

Research Meta-Research, Feasibility Study, Scientific and Technical Research

Consulting Healthcare Consulting

Data & AI Statistical Analysis, Image Processing, Image Analysis

Product Development Product Evaluation, Product Validation, Manufacturing

Work Experience

Syneos Health (United States)

- Present

Clinical Study Manager

Syneos Health (Previously INCResearch)

October 2023 - November 2025

Clinical Site Manager

CHU de Quebec

May 2018 - October 2023

Clinical Site manager and research associate

IRCM

January 2012 - May 2018

Education

PhD

Université Laval - Canada

June 2003 - December 2007

PhD (biology)

Université Laval

May 2003 - December 2007

Certifications

• Certified Six Sigma Yellow Belt

  Université Laval

  June 2011 - Present

Publications

JOURNAL ARTICLE

Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É, Castonguay V, Marcoux N, Lodde M, et al. (2024). Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study . Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Desy A, Bouvet GF, Lafrenière N, Zamanian A, Després P, Beauregard JM (2022). Impact of the dead-time correction method on quantitative ¹⁷⁷Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy . EJNMMI physics.

Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte É, Rousseau É, Probst S, Kassouf W, Anidjar M, et al. (2021). The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol . BJU international.

Desy A, Bouvet GF, Croteau É, Lafrenière N, Turcotte ÉE, Després P, Beauregard JM (2021). Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems . EJNMMI physics.

Bouvet GF, Bulka O, Coriati A, Sognigbé L, St-Pierre G, Massé C, Sato S, Berthiaume Y (2021). Peripheral blood mononuclear cell response to YKL-40 and Galectin-3 in cystic fibrosis . Cytokine.

Coriati A, Bouvet GF, Massé C, Ducruet T, Berthiaume Y (2020). YKL-40 as a clinical biomarker in adult patients with CF: Implications of a CHI3L1 single nucleotide polymorphism in disease severity . Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Desy A, Bouvet GF, Frezza A, Després P, Beauregard JM (2020). Impact of dead time on quantitative ¹⁷⁷Lu-SPECT (QSPECT) and kidney dosimetry during PRRT . EJNMMI physics.

Bouvet GF, Voisin G, Cyr Y, Bascunana V, Massé C, Berthiaume Y (2018). DNA Methylation Regulates RGS2-induced S100A12 Expression in Airway Epithelial Cells . American journal of respiratory cell and molecular biology.

Coriati A, Massé C, Ménard A, Bouvet GF, Berthiaume Y (2018). Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis . Inflammation.

Coriati A, Arslanian E, Bouvet GF, Prat A, Seidah NG, Rabasa-Lhoret R, Berthiaume Y (2017). Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis . Clinical and investigative medicine. Medecine clinique et experimentale.

Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y (2017). Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis . Medicine and science in sports and exercise.

Bouvet GF, Maignan M, Arslanian E, Coriati A, Rabasa-Lhoret R, Berthiaume Y (2014). Association between serum YKL-40 level and dysglycemia in cystic fibrosis . Cytokine.

Boncoeur É, Bouvet GF, Migneault F, Tardif V, Ferraro P, Radzioch D, de Sanctis JB, Eidelman D, Govindaraju K, Dagenais A, et al. (2013). Induction of nitric oxide synthase expression by lipopolysaccharide is mediated by calcium-dependent PKCα-β1 in alveolar epithelial cells . American journal of physiology. Lung cellular and molecular physiology.

Bouvet GF, Jacobi V, Plourde KV, Bernier L (2007). Stress-induced mobility of OPHIO1 and OPHIO2, DNA transposons of the Dutch elm disease fungi . Fungal genetics and biology : FG & B.